eyecro data to be presented at ARVO 2016 in Seattle
Similar Posts
eyecro’s First Published Article in Molecular and Cellular Biology
Retinol-Binding Protein 4 Induces Inflammation in Human Endothelial Cells by a NADPH Oxidase- and Nuclear Factor Kappa B-dependent and Retinol-Independent Mechanism Krysten M. Farjoa,#, Rafal A. Farjob, Stacey Halseya, Gennadiy Moiseyeva and Jian-xing Maa aDepartment of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma beyecro LLC, Oklahoma City, Oklahoma ABSTRACT Serum retinol-binding protein…
NIH-Industry Collaboration Advances Gene-Agnostic Treatment for Retinal Disease
A new study from the National Institutes of Health (NIH) has shown promising results for reserpine—a medication originally approved in 1955 for high blood pressure—as a potential treatment to prevent vision loss caused by inherited blinding diseases such as retinitis pigmentosa. In preclinical studies, reserpine protected retinal neurons essential for vision, particularly in females. Unlike…
Calvert Labs and eyecro Announce Strategic Partnership in Ocular Research
Scott Township, PA – June 10, 2013 – Calvert Labs and eyecro, two leading providers in early-stage ocular drug research and development, announced today that they have entered into a strategic partnership to expedite preclinical drug development activities. “This partnership will facilitate a seamless transition from the discovery and non-GLP stage of drug development to…
EyeCRO and MPI Research Partner to Develop New Preclinical Models of Ophthalmic Disease
Oklahoma City, OK; Ann Arbor, MI; and Mattawan, MI (PRWEB) May 01, 2017 eyecro and MPI Research, two global leaders in preclinical ophthalmology contract research, today announced a collaboration to develop and commercialize large mammalian preclinical models for various ophthalmic diseases, including Age-Related Macular Degeneration and Diabetic Retinopathy. The partnership leverages the unique skills and…
eyecro COO Gives Talk at ARVO
“Dr. Rafal Farjo, Chief Operating Officer of eyecro, gives a seminar to Members-in-Training on Transitioning from Academia to a Start-up. At the 2013 Annual meeting of the Association for Research in vision and Ophthalmology in Seattle.”
EyeCRO conducts successful pre-IND meeting with US Food and Drug Administration to discuss CsA-MIDROPS™
EyeCRO recently requested and conducted a pre-IND meeting with the US FDA to discuss the nonclinical and clinical development plans for CsA-MiDROPS™ to treat Dry Eye Disease. The agency was supportive of the project and agreed that the proposed nonclinical and CMC studies would allow entry into a phase II clinical trial. Also discussed was…
